Den europeiske union - norsk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

intervet international bv - indoxacarb, permethrin - permethrin, kombinasjoner, ectoparasiticides for utvortes bruk, inkl. insektmidler - hunder - behandling av loppeinfeksjoner (ctenocephalides felis); produktet har vedvarende insekticid effekt i opptil 4 uker mot ctenocephalides felis. produktet har vedvarende akaricid effekt i opptil 5 uker mot ixodes ricinus og opptil 3 uker mot rhipicephalus sanguineus. en behandling gir frastøtende (anti-fôring) aktivitet mot sand fluer (phlebotomus perniciosus) for opp til 3 uker.

Den europeiske union - norsk - EMA (European Medicines Agency)

zoetis belgium sa - levende aroa-gen slettet escherichia coli, type 078, stamme ec34195 - immunologicals for aves, live bakteriell vaksiner - chicken; turkeys - for aktiv immunisering av broilerkyllinger og fremtidige lag / oppdrettere for å redusere dødelighet og lesjoner (perikarditt, perihepatitt, airsacculitt) assosiert med escherichia coli serotype o78.

Norge - norsk - Statens legemiddelverk

intervet international bv - 5831 an - permetrin - påflekkingsvæske, oppløsning - 715 mg/ ml

Norge - norsk - Statens legemiddelverk

mylan ireland limited - kaspofunginacetat - pulver til konsentrat til infusjonsvæske, oppløsning - 50 mg

Norge - norsk - Statens legemiddelverk

mylan ireland limited - kaspofunginacetat - pulver til konsentrat til infusjonsvæske, oppløsning - 70 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 320 mikrog / 9 mikrog

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 80 mikrog/ dose / 4.5 mikrog/ dose

Den europeiske union - norsk - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om å innlede behandling i paediatric pasienter se kapittel 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for hepatitt c-virus (hcv) genotypen bestemt aktivitet, se kapittel 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når du bestemmer deg for å starte behandling i barndommen, er det viktig å vurdere vekst hemming indusert ved kombinasjonsbehandling. den reversibilitet av vekst hemming er usikker. beslutningen om å behandle bør gjøres på en sak til sak-basis (se kapittel 4.

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - budesonid - inhalasjonspulver - 400 mikrog/ dose